The new vehicle will be managed by London, UK-based life sciences venture capital firm SV Life Sciences (SVLS).
Investors included the UK Government’s Department of Health (DoH) and Alzheimer’s Research UK alongside major pharmaceutical companies including Biogen, GlaxoSmithKline, Johnson & Johnson, Lilly, Pfizer and Takeda.
The fund has been established to deliver new drug approaches for dementia by 2025 to diagnose and intervene early to modify the course of disease while improving symptoms and thereby laying the foundations for effective therapies.
It will work collaboratively with universities, academic institutes and the biotechnology and pharmaceutical industry internationally to identify novel dementia research projects and nurture these through the pre-clinical phase, enabling further development in clinical trials.
Priorities are to explore and develop novel hypotheses in dementia research and to increase global interest and industry confidence in the value of dementia research.